CAUTION......DON'T SELL RIDAFOROLIMUS SHORT
It amazes me to see how many posters discuss Rida in such a "ho hum" fashion and believe that Rida does not have a very good chance of getting approved for sarcoma and has a slim to none chance of producing any meaningful revenue.
I disagree with these assessments and actually believe that Rida can be a blockbuster. I believe this for several reasons:
1- Affinitor
2- Multiple indications
3- Merck
The most logical means to assess a drugs sales prospects, is to use a similiar drug that has already been approved. In the case of Rida, we have a similiar drug that has already been approved and that drug is Affinitor (NVS). Like Rida, Affinitor is an MTOR inhibitor. Though it has only been approved for kidney cancer at present, Affinitor is also in the clinic in other indications, such as breast cancer. In the first 9 months of 2010, Affinitor (with only the kidney cancer approval) rang up 163 million, or an annual rate of 217 million. Experts are predicting that with other indications being approved, Affinitor will be a block buster with annual sales over one billion and some estimates running as high as 5 billion annually.
Rida, like Affinitor, is also a multi targeted drug, and as we here well know, is in the clinic for other indications (other than sarcoma) including breast cancer, endometrial cancer, prostate cancer etc.
Do these posters I referred to actually believe that Merck committed about $1,000,000,000.00 to a drug that simply may be the first drug in 20 years to treat sarcoma, and as some believe here, only has a 50/50 shot at meeting it's endpoint to serve that small market? I don't think so.
I CAUTION AGAIN..... DON'T SELL RIDAFOROLIMUS SHORT
